Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study aims to Fine-Tune antibiotic dosing for ICU patients

NCT ID NCT07681544

Knowledge-focused Sponsor: Hospital Italiano de Buenos Aires Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study looks at how the antibiotic meropenem behaves in the blood of critically ill adults in the intensive care unit. Researchers compare different doses (1 gram vs. 2 grams) and infusion times (30 minutes vs. 3 hours) to see which keeps drug levels above the needed threshold longer. Participants receive meropenem as part of standard care and provide blood samples during the first 48 hours. The goal is to help doctors choose the best dosing strategy for treating infections before the exact bacteria are known.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
meropenem
What this could lead to
If successful, this study could help doctors choose the best meropenem dose and infusion method for critically ill patients, potentially improving infection treatment.
What could go wrong
This is a small observational study with only 26 participants, so results may not apply to all patients. It does not test a new drug or directly measure patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

26 people

The number who actually took part.

Started

Jun 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥18 years of age. * Hospitalization in the Intensive Care Unit (ICU), Intermediate Care Unit (ICU step-down/IMCU), or Coronary Care Unit (CCU). * Receipt of empiric meropenem therapy for at least 24 hours, regardless of the site of infection. * Written informed consent provided by the patient or their legally authorized representative prior to study participation. Exclusion Criteria: * History of severe adverse reactions to meropenem. * Availability of microbiological identification results prior to blood sampling for meropenem concentration measurement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critically ill are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critically ill Empirical antimicrobial therapy Meropenem Pharmacokinetics and pharmacodynamics

Contacts and locations

Locations

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.